Executive Board
The Executive Board has been established to assist the Chief Executive in leading The Institute of Cancer Research to achieve its strategic aims and objectives within the approved strategies and budgets and is responsible for formulating strategies, plans and budgets for approval by the Board of Trustees.
Professor Kristian Helin
Chief Executive and President
Professor Kevin Harrington
Head of Division – Radiotherapy and Imaging
Professor Clare Isacke
Dean of Academic and Research Affairs
Paul Norris
Chief Financial Officer
Jonathan Monk
Chief Information Officer
Professor Jonathon Pines
Head of Division – Cell and Molecular Biology
Dr Barbara Pittam
Chief Research and Academic Officer
Dr Olivia Rossanese
Head of Division – Cancer Therapeutics
Dr Kary Kelly
Chief Development and Communications Officer
Latest ICR News
National breast cancer audit helps inform debate over surgical margins for ductal carcinoma in situ
A large national study has provided some of the strongest evidence yet on how much healthy tissue should be removed when treating ductal carcinoma in situ (DCIS) with breast-conserving surgery – helping to resolve a long-running clinical debate and prompting changes to the Association of Breast Surgeons guidance.
Immunotherapy uses invisibility cloak to deliver direct hit to prostate cancer
A new immunotherapy drug has shown promise for safely treating prostate cancer, a phase I trial reports.
.jpg?sfvrsn=205a5de0_2 "Castration resistant prostate cancer cells stained for a number of key driver molecules. (Mateus Crespo, Gerhardt Attard and Johann de Bono / the ICR, 2012)")
Targeted radiotherapy injection shrinks treatment-resistant prostate cancer tumours in early clinical trial
A new drug for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep cancer at bay, a phase I trial reports.
Researchers overcome major obstacle in targeted protein degradation
In a significant advancement, cancer researchers have found a long-sought way to overcome a critical design barrier in the generation of small-molecule chemical tools and drugs that work by targeted protein degradation.